Trump Announces Pricing Deals With Nine Drugmakers

Deal Overview

President Donald Trump announced a new agreement with nine major pharmaceutical manufacturers. Under the pact, the companies will sell the bulk of their medicines to Medicaid at price levels that match those charged in European markets.

Direct‑to‑Consumer Sales via TrumpRx

The arrangement also includes the launch of a dedicated online platform, TrumpRx. Through this website, consumers will be able to purchase prescription drugs directly, bypassing traditional pharmacy channels and benefiting from the reduced pricing structure.

Implications for Patients and the Industry

Supporters contend that aligning U.S. drug prices with European standards could significantly lower out‑of‑pocket costs for millions of Americans, particularly those enrolled in Medicaid. Critics, however, warn that the long‑term impact on pharmaceutical research funding and market dynamics remains uncertain.